Influenza A and B viruses are among the most significant global health threats, responsible for annual epidemics and occasional pandemics with substantial morbidity and mortality. The high mutation rate of the influenza genome, driven by antigenic drift and shift, allows the virus to evade host immunity, necessitating annual vaccine updates and continuous surveillance. The viral surface glycoproteins — hemagglutinin (HA) and neuraminidase (NA) — are major targets for neutralizing antibodies and antiviral drugs, while internal proteins such as nucleoprotein (NP), matrix protein 1 (M1), and non-structural protein 1 (NS1) serve as conserved targets for diagnostics, vaccine platforms, and understanding viral pathogenesis. The emergence of novel subtypes (H1N1, H3N2, H5N1, H7N9, etc.) and zoonotic strains further underscores the urgent need for robust research tools to accelerate vaccine development, antiviral screening, and immunological studies.

AntibodySystem offers a comprehensive portfolio of high-quality monoclonal antibodies, recombinant proteins, biosimilars, and ELISA kits targeting key influenza antigens across multiple subtypes. Our products are rigorously validated for ELISA, Western blot, immunohistochemistry, neutralization assays, and other applications, providing researchers with reliable reagents for antigen detection, serological analysis, and functional studies. From subtype-specific HA and NA recombinant proteins to antibodies against conserved internal proteins (NP, M1, NS1) and ready-to-use quantitative ELISA kits, our portfolio supports the full spectrum of influenza research — from basic virology and vaccine efficacy evaluation to antiviral drug discovery and diagnostic development.